Science Corporation raises $400M to expand brain and vision implants

Covered by 2 sources
Read onTechCrunch· 2 min
Science Corporation raised $400 million in Series D funding, reaching a $3.5 billion valuation. The company plans to expand access to its PRIMA retinal implant in Europe, prepare for a U.S. launch, and advance biohybrid neural-interface research. PRIMA is a CE-marked implantable chip that aids vision restoration in certain macular degeneration cases, and the company is also pursuing treatments for brain-related conditions.

What happened

Science Corporation, a company founded by Max Hodak in 2021, has raised $400 million in a Series D funding round. This new investment brings the company’s total funding to over $900 million and values it at $3.5 billion. The funds will be used to expand access to its PRIMA retinal implant in Europe, prepare for a US launch, and further develop its biohybrid neural-interface technology. PRIMA is a brain-computer interface designed to help restore vision in people with certain types of macular degeneration.

Key details

  • PRIMA is CE-marked in the European Union for restoring form vision in late-stage macular degeneration.
  • The implant has 378 light-powered pixels and works with special glasses to stimulate retinal cells.
  • At 12 months, 80% of clinical study participants showed significant improvement in visual acuity.
  • PRIMA has received two FDA Humanitarian Use Device designations but is not yet approved for sale in the US.
  • The company is also developing a biohybrid neural-interface that uses engineered neurons to connect with the brain.

Why it matters

Patients with advanced macular degeneration in Europe can now access a new vision-restoring device, while those in the US may see it become available if regulatory approval is granted. Investors and healthcare providers are directly affected by the company’s increased valuation and the expansion of clinical trials for conditions like Stargardt’s disease. The funding also supports further research into neural interfaces, which could lead to new treatments for brain-related conditions in the future.

Also covered by 1 source


More in Healthcare